Replies to post #233259 on Biotech Values

[DewDiligence]

MYOV—(-23%)—misses secondary endpoint in CSPC phase-3 comparing relugolix to Lupron:

https://www.globenewswire.com/news-release/2020/09/29/2100606/0/en/Myovant-Sciences-Announces-Results-of-Additional-Secondary-Endpoint-of-Castration-Resistance-Free-Survival-from-Phase-3-HERO-Study-of-Relugolix-in-Advanced-Prostate-Cancer.html

This trial previously met its primary endpoint, and relugolix is under FDA review with a 12/20/20 PDUFA date.